Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Henrik Stenqvist will be appointed Chief Financial Officer (CFO) and will join Sobi in late spring. Henrik will be a member of Sobi’s Executive Committee.
Henrik Stenqvist has comprehensive experience from the pharmaceutical industry with 25 years in finance and management positions. He joins Sobi from a position as CFO of Recipharm. Prior to that, Henrik Stenqvist served as the CFO of the Meda Group, where he played an instrumental role in the transformation of Meda from a small Nordic player to a leading international specialty pharma, executing numerous acquisitions as well as the integration of these.
Henrik Stenqvist holds a degree in Finance and Business Administration from the University of Linköping, Sweden.
“It is a pleasure to welcome Henrik to Sobi. His experience from the pharmaceutical industry and specifically from acquisitions and deal making in specialty pharma will be of immense value for Sobi on our journey to become a global leader in rare diseases and specialty care”, says Guido Oelkers, CEO and President of Sobi.
“I am very happy to be joining Sobi and I believe that I, through my experience, can contribute to realising Sobi’s growth strategy”, says Henrik Stenqvist.
Sobi’s current CFO, Mats-Olof Wallin, will support the transition process and will retire by year-end 2018. Mats-Olof Wallin has been an important contributor in the management of Sobi and for the Group to become a company with healthy top-line and earnings growth.
Source: Sobi
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
